Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

690 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.
Montesinos P, Roboz GJ, Bulabois CE, Subklewe M, Platzbecker U, Ofran Y, Papayannidis C, Wierzbowska A, Shin HJ, Doronin V, Deneberg S, Yeh SP, Ozcan MA, Knapper S, Cortes J, Pollyea DA, Ossenkoppele G, Giralt S, Döhner H, Heuser M, Xiu L, Singh I, Huang F, Larsen JS, Wei AH. Montesinos P, et al. Among authors: dohner h. Leukemia. 2021 Jan;35(1):62-74. doi: 10.1038/s41375-020-0773-5. Epub 2020 Mar 16. Leukemia. 2021. PMID: 32203138 Free PMC article. Clinical Trial.
Acute myeloid leukaemia.
Estey E, Döhner H. Estey E, et al. Among authors: dohner h. Lancet. 2006 Nov 25;368(9550):1894-907. doi: 10.1016/S0140-6736(06)69780-8. Lancet. 2006. PMID: 17126723 Review.
Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
Heidel F, Cortes J, Rücker FG, Aulitzky W, Letvak L, Kindler T, Huber C, Döhner H, Kantarjian H, Fischer T. Heidel F, et al. Among authors: dohner h. Cancer. 2007 Mar 1;109(5):907-14. doi: 10.1002/cncr.22471. Cancer. 2007. PMID: 17285599 Free article. Clinical Trial.
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group. Schlenk RF, et al. Among authors: dohner k, dohner h. N Engl J Med. 2008 May 1;358(18):1909-18. doi: 10.1056/NEJMoa074306. N Engl J Med. 2008. PMID: 18450602 Free article.
Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.
Gaidzik VI, Schlenk RF, Moschny S, Becker A, Bullinger L, Corbacioglu A, Krauter J, Schlegelberger B, Ganser A, Döhner H, Döhner K; German-Austrian AML Study Group. Gaidzik VI, et al. Among authors: dohner k, dohner h. Blood. 2009 May 7;113(19):4505-11. doi: 10.1182/blood-2008-10-183392. Epub 2009 Feb 12. Blood. 2009. PMID: 19221039 Free article. Clinical Trial.
High-dose daunorubicin in older patients with acute myeloid leukemia.
Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, van Marwijk Kooy M, Verdonck LF, Beck J, Döhner H, Gratwohl A, Pabst T, Verhoef G; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON); German AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. Löwenberg B, et al. Among authors: dohner h. N Engl J Med. 2009 Sep 24;361(13):1235-48. doi: 10.1056/NEJMoa0901409. N Engl J Med. 2009. PMID: 19776405 Free article. Clinical Trial.
690 results